We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

63 hedge funds and large institutions have $43M invested in Cue Biopharma in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $207K | Put options by funds: $103K

23% more capital invested

Capital invested by funds: $35.1M → $43M (+$7.97M)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

3% more funds holding

Funds holding: 61 → 63 (+2)

0.06% less ownership

Funds ownership: 0.99% → 0.93% (-0.06%)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
13
Reduced
17
Closed
9
Calls
$207K
Puts
$103K
Net Calls
+$104K
Net Calls Change
-$22K

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$435K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$421K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$396K
4
Citadel Advisors
Citadel Advisors
Florida
+$285K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$280K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$2.19M
2
GCP
GSA Capital Partners
United Kingdom
-$366K
3
CC
Carlson Capital
Texas
-$353K
4
BL
Bleichroeder LP
New York
-$338K
5
Renaissance Technologies
Renaissance Technologies
New York
-$288K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$8.58M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$5.9M +$396K +4,156 +8%
PM
3
Prosight Management
Texas
$4.11M -$2.19M -22,955 -37%
BL
4
Bleichroeder LP
New York
$2.7M -$338K -3,541 -12%
BlackRock
5
BlackRock
New York
$2.37M -$120K -1,258 -5%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$1.95M +$280K +2,931 +19%
RSWM
7
Robertson Stephens Wealth Management
California
$1.71M – – –
MAM
8
Monaco Asset Management
Monaco
$1.66M -$98K -1,028 -6%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$1.62M +$435K +4,564 +43%
Millennium Management
10
Millennium Management
New York
$1.23M -$93.4K -979 -8%
SCM
11
Silverarc Capital Management
Massachusetts
$1.09M – – –
AR
12
Advisory Research
Illinois
$918K – – –
CC
13
Carlson Capital
Texas
$907K -$353K -3,699 -30%
SPC
14
Sigma Planning Corp
Michigan
$789K +$89.6K +939 +15%
Bank of America
15
Bank of America
North Carolina
$598K +$224K +2,349 +73%
PAWC
16
P.A.W. Capital
Connecticut
$536K -$95.4K -1,000 -17%
Stifel Financial
17
Stifel Financial
Missouri
$523K +$51.2K +537 +12%
State Street
18
State Street
Massachusetts
$504K – – –
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$473K +$421K +4,418 New
VC
20
Voss Capital
Texas
$446K – – –
Citadel Advisors
21
Citadel Advisors
Florida
$377K +$285K +2,988 +560%
Morgan Stanley
22
Morgan Stanley
New York
$353K -$254K -2,662 -45%
NCM
23
Nantahala Capital Management
Connecticut
$333K – – –
Northern Trust
24
Northern Trust
Illinois
$280K +$50K +524 +25%
HighTower Advisors
25
HighTower Advisors
Illinois
$272K +$242K +2,537 New
1
2 3

CUE Hedge Fund Activity: Q1 2023 in Review

63 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2023, worth a combined $43M — up 23% from $35.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 9 closed out — a net gain of 2 holders — while 13 added to existing stakes and 17 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $435K. The largest seller was Prosight Management, cutting an estimated $2.19M.

  • 63 institutional investors held Cue Biopharma (CUE) as of Q1 2023, up from 61 in Q4 2022.
  • Funds reported $43M of Cue Biopharma stock for Q1 2023, up 23% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q1 2023 and 9 closed out, a net change of +2 holders.
  • The largest Cue Biopharma buyer in Q1 2023 was Geode Capital Management, an estimated $435K added.
  • The largest Cue Biopharma seller in Q1 2023 was Prosight Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q1 2023.